<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332955</url>
  </required_header>
  <id_info>
    <org_study_id>2010-023287-41</org_study_id>
    <secondary_id>ANRS HC26 TelapreVIH</secondary_id>
    <nct_id>NCT01332955</nct_id>
  </id_info>
  <brief_title>Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen</brief_title>
  <acronym>TelapreVIH</acronym>
  <official_title>Pilot Study of PegInterferon-Ribavirin-Telaprevir Efficacy and Tolerability in HIV-HCV Coinfected Patients Who Had Previously Failed a PegInterferon-Ribavirin Regimen. (ANRS HC26 TelapreVIH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II, multicentric, national pilot trial is designed to estimate the sustained&#xD;
      virological response rate (SVR) following a 12 weeks treatment by telaprevir combined with a&#xD;
      48 or 72 weeks treatment by peginterferon and ribavirin, based upon the rapid virological&#xD;
      response (RVR) at week 8 (4 weeks after telaprevir start), and to compare the observed SVR to&#xD;
      20%, a rate determining a significant therapeutic benefit in this population of patients. The&#xD;
      primary endpoint will be the SVR defined as undetectable HCV-RNA measured 24 weeks after the&#xD;
      end of therapy (EOT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase II pilot trial is designed for HIV-1 and HCV genotype 1 coinfected patients who&#xD;
      had previously failed a peginterferon-ribavirin regimen.&#xD;
&#xD;
      Intervention Design:&#xD;
&#xD;
        -  Induction, Lead-in, phase: day 0 to week 4 PegInterferon alpha-2a, 180 µg subcutaneous&#xD;
           injection, once weekly + Ribavirin (weight-based dose) 1000 mg for subjects weighing &lt;75&#xD;
           kg or 1200 mg for subjects weighing ≥75 kg, b.i.d.&#xD;
&#xD;
        -  Telaprevir phase: week 4 to week 16 PegInterferon alpha-2a, 180 µg subcutaneous&#xD;
           injection, once weekly + Ribavirin (weight-based dose) 1000 mg for subjects weighing &lt;75&#xD;
           kg or 1200 mg for subjects weighing ≥75 kg, b.i.d.&#xD;
&#xD;
           + Telaprevir 750 mg q 8h (or 1125 mg q 8h in association with Efavirenz)&#xD;
&#xD;
        -  Maintenance phase: week 16 to week 48 or 72 PegInterferon alpha-2a, 180 µg subcutaneous&#xD;
           injection, once weekly + Ribavirin (weight-based dose) 1000 mg for subjects weighing &lt;75&#xD;
           kg or 1200 mg for subjects weighing ≥75 kg, b.i.d.&#xD;
&#xD;
      The duration of the maintenance phase is determined by the RVR at week 8 (4 weeks after&#xD;
      Telaprevir start.&#xD;
&#xD;
      Complete RVR (not measurable HCV-RNA at week 8): maintenance from week 16 to week 48&#xD;
&#xD;
      _Partial RVR (HCV-RNA below 1 000 UI/mL but still measurable at week 8): maintenance phase&#xD;
      from week 16 to week 48&#xD;
&#xD;
      And stable antiretroviral treatment for over 3 months among the authorized combinations:&#xD;
      (tenofovir 300 mg, emtricitabine 200 mg, atazanavir 300 mg, ritonavir 100 mg) q.d. or&#xD;
      (tenofovir 300 mg, emtricitabine 200 mg, efavirenz 600 mg) q.d. or (tenofovir 300 mg,&#xD;
      emtricitabine 200 mg q.d. and raltegravir 400 mg b.i.d.) once Drug-Drug interaction data will&#xD;
      be available. Patients who could not receive one of these 3 combinations can be included if&#xD;
      they are receiving a stable combination of at least 3 drugs among the following: tenofovir,&#xD;
      emtricitabine/lamivudine, efavirenz, atazanavir-boosted or not, raltegravir (once Drug-Drug&#xD;
      interaction data will be available). These patients cannot participate in the pharmacokinetic&#xD;
      study.&#xD;
&#xD;
      The trial will enroll 80 subjects. The proportion of patients included, presenting with&#xD;
      cirrhosis (METAVIR F4) will remain below 50% of all patients The proportion of patients&#xD;
      included, null-responders to previous HCV treatment (HCV-RNA decline at week 12 less than 2&#xD;
      log10 UI/ml) but no cirrhosis (maximum equal METAVIR F3) will remain below 30% of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of SVR following a 12 wks treatment by telaprevir combined with a 48 or 72 wks peginterferon-ribavirin treatment, based upon the rapid virological response, and comparison to 20% (which would correspond to a significant therapeutic benefit)</measure>
    <time_frame>up to 92 weeks or 116 weeks depending on rapid virologic response</time_frame>
    <description>HCV-RNA measured 24 weeks after the end of HCV treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>From week 0 up to 92 weeks or 116 weeks depending on rapid virologic response</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of the Sustained Virological Response defined as undetectable HCV-RNA at Week 12 after the end of HCV treatment</measure>
    <time_frame>at Week 60 or Week 84 depending on rapid virologic response</time_frame>
    <description>HCV-RNA measured 12 weeks after the end of HCV treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Telaprevir-pegIFN alfa-2a-ribavirine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Group Assignment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telaprevir</intervention_name>
    <description>Drug : telaprevir, Tablet, Oral, 750 mg, q8h, 12 weeks if associated with atazanavir or raltegravir&#xD;
Drug : telaprevir, Tablet, Oral, 1125 mg, q8h, 12 weeks if associated with efavirenz</description>
    <arm_group_label>Telaprevir-pegIFN alfa-2a-ribavirine</arm_group_label>
    <other_name>VX-950</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegIFN alfa-2a</intervention_name>
    <description>Subcutaneous injection, 180 μg, once weekly, 48 weeks or 72 weeks</description>
    <arm_group_label>Telaprevir-pegIFN alfa-2a-ribavirine</arm_group_label>
    <other_name>peginterferon alfa-2a, Pegasys®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>(weight-based dose) Tablet, Oral, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, 48 weeks or 72 weeks</description>
    <arm_group_label>Telaprevir-pegIFN alfa-2a-ribavirine</arm_group_label>
    <other_name>Copegus®</other_name>
    <other_name>Rebetol®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent form signed at screening visit at the latest&#xD;
&#xD;
          -  Patient registered with or covered by a social security scheme&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  Chronic, genotype 1, hepatitis C with detectable HCV RNA at screening&#xD;
&#xD;
          -  Virological failure following a previous treatment of at least 12 weeks by&#xD;
             peginterferon alpha-2a ≥ 135 µg once weekly or peginterferon alpha-2b ≥ 1.0 µg per kg&#xD;
             once weekly + ribavirin ≥ 600 mg once daily. Virological failure defined by&#xD;
             persistence of a detectable HCV-RNA, with the same genotype than before. Null&#xD;
             responder patient, with less than 2 Log10 HCV-RNA decline at week 12 with cirrhosis&#xD;
             are excluded from the study. Null responder patients without cirrhosis (equal or below&#xD;
             METAVIR F3) are limited to less than 30 % of all patients included&#xD;
&#xD;
          -  No Interferon and/or Ribavirin within past 6 months&#xD;
&#xD;
          -  Stable antiretroviral treatment for over 3 months at screening. Authorized&#xD;
             combinations: tenofovir-emtricitabine-boosted&#xD;
             atazanavir,tenofovir-emtricitabine-efavirenz,tenofovir-emtricitabine-raltegravir, once&#xD;
             Drug-Drug interaction data will be available. Patients with a stable combination of at&#xD;
             least 3 of the following drugs: tenofovir, emtricitabine/lamivudine, efavirenz,&#xD;
             atazanavir-boosted or not, raltegravir. These patients cannot participate in the&#xD;
             pharmacokinetic study&#xD;
&#xD;
          -  CD4 &gt;200/mm3 and &gt;15% at screening&#xD;
&#xD;
          -  Plasma HIV-RNA &lt;50 copies/mL for at least 6 months at screening visit&#xD;
&#xD;
          -  Body weight ≥ 40 kg to equal or below 125 kg&#xD;
&#xD;
          -  Fibrosis stage have to be documented by a significant liver biopsy (cumulative length&#xD;
             ≥ 15 mm or ≥ 6 portal spaces), within 3 years. Patients with a previous liver biopsy&#xD;
             exhibiting cirrhosis lesions (METAVIR F4) are allowed to enter the study without a new&#xD;
             biopsy. The proportion of patients with cirrhosis lesions (METAVIR F4) is limited to&#xD;
             50% of all patients.&#xD;
&#xD;
          -  Male patients, female patients with child-bearing potency and their heterosexual&#xD;
             partners must use an adequate contraception from 1 month before initiation of&#xD;
             treatment to 7 months following the end of treatment for men and to 4 months following&#xD;
             the end of treatment for women. Subjects (or their female partners) must not be&#xD;
             pregnant or planning to become pregnant within 2 years after enrolling in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with liver failure (Child B and C) or past history of decompensated cirrhosis&#xD;
&#xD;
          -  Significant oesophageal varices (Stages 2-3) on a gastrointestinal endoscopy within 3&#xD;
             years&#xD;
&#xD;
          -  Detectable AgHBs&#xD;
&#xD;
          -  HIV-2 co-infection&#xD;
&#xD;
          -  Contra-indication to ribavirin or peginterferon&#xD;
&#xD;
          -  Severe pre-existing cardiac or pulmonary disease&#xD;
&#xD;
          -  Untreated dysthyroidism&#xD;
&#xD;
          -  Uncontrolled Type 2 diabetes&#xD;
&#xD;
          -  Optic neuritis past history and retinal condition&#xD;
&#xD;
          -  History of organ transplant&#xD;
&#xD;
          -  Severe hemoglobinopathy&#xD;
&#xD;
          -  Congenital QT prolongation, family history of congenital QT prolongation or sudden&#xD;
             unexpected death&#xD;
&#xD;
          -  Contra-indication to telaprevir, hypersensitivity to any component of the drug product&#xD;
&#xD;
          -  Any disease requiring long term, systemic corticotherapy or immunosuppressive therapy&#xD;
             during study&#xD;
&#xD;
          -  Alcohol intake that may represent an obstacle for the participation of the subject&#xD;
&#xD;
          -  Substance abuse that may represent an obstacle for the participation of the subject&#xD;
&#xD;
          -  Acute CDC stage C opportunistic infection within the previous 6 months&#xD;
&#xD;
          -  Past history of cancer within the previous 5 years (except skin basal cell carcinoma,&#xD;
             Kaposi's disease in stable remission, in situ cervical cancer and in situ anal cancer)&#xD;
&#xD;
          -  Any active malignant disease including hepatocellular carcinoma&#xD;
&#xD;
          -  Patients unable to observe the study procedures&#xD;
&#xD;
          -  Participation to another clinical trial within the previous 30 days&#xD;
&#xD;
          -  Haemoglobin &lt;120 g/L for women and &lt;130 g/L for men&#xD;
&#xD;
          -  Platelets &lt;90 000/mm3&#xD;
&#xD;
          -  Neutrophils &lt;1 500/mm3&#xD;
&#xD;
          -  Renal insufficiency defined by an estimated Glomerular Filtration Rate &lt; 60 mL/mn&#xD;
             (MDRD equation)&#xD;
&#xD;
          -  Associated medication susceptible to interfere with the pharmacokinetic parameters of&#xD;
             telaprevir and/or antiretroviral associated drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent COTTE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Croix Rousse LYON FRANCE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Pierre ABOULKER, MD</last_name>
    <role>Study Chair</role>
    <affiliation>INSERM SC10 VILLEJUIF FRANCE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service Maladies Infectieuses et Tropicales, Hôpital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.anrs.fr</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>March 28, 2011</study_first_submitted>
  <study_first_submitted_qc>April 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <last_update_submitted>January 22, 2014</last_update_submitted>
  <last_update_submitted_qc>January 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>HIV Infection</keyword>
  <keyword>Telaprevir</keyword>
  <keyword>Peginterferon alfa-2a</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Pharmacogenetic</keyword>
  <keyword>Previous peginterferon-ribavirin regimen failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

